Renalytix plc raised £7m from its recent share placing, subscription and retail offer as it seeks to expand its product into the US market.

The precision medicine diagnostics company is behind kidneyintelX.dkd, which claims to be the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease.